LT2621493T - N1-pirazolo-spiro-ketono acetil-coa-karboksilazės inhibitoriai - Google Patents
N1-pirazolo-spiro-ketono acetil-coa-karboksilazės inhibitoriaiInfo
- Publication number
- LT2621493T LT2621493T LTEP11768163.5T LT11768163T LT2621493T LT 2621493 T LT2621493 T LT 2621493T LT 11768163 T LT11768163 T LT 11768163T LT 2621493 T LT2621493 T LT 2621493T
- Authority
- LT
- Lithuania
- Prior art keywords
- coa carboxylase
- carboxylase inhibitors
- pyrazolospiroketone
- acetyl
- pyrazolospiroketone acetyl
- Prior art date
Links
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38810210P | 2010-09-30 | 2010-09-30 | |
| PCT/IB2011/054119 WO2012042433A1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2621493T true LT2621493T (lt) | 2016-10-25 |
Family
ID=44789556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11768163.5T LT2621493T (lt) | 2010-09-30 | 2011-09-20 | N1-pirazolo-spiro-ketono acetil-coa-karboksilazės inhibitoriai |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8859577B2 (enExample) |
| EP (1) | EP2621493B1 (enExample) |
| JP (1) | JP5824055B2 (enExample) |
| CA (1) | CA2811033C (enExample) |
| CY (1) | CY1118016T1 (enExample) |
| DK (1) | DK2621493T3 (enExample) |
| ES (1) | ES2602111T3 (enExample) |
| HR (1) | HRP20161178T1 (enExample) |
| HU (1) | HUE031616T2 (enExample) |
| LT (1) | LT2621493T (enExample) |
| PL (1) | PL2621493T3 (enExample) |
| PT (1) | PT2621493T (enExample) |
| RS (1) | RS55224B1 (enExample) |
| SI (1) | SI2621493T1 (enExample) |
| WO (1) | WO2012042433A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198483A1 (en) | 2003-04-03 | 2004-10-07 | Amaitis Lee M. | System and method for betting on a subset of participants in an event |
| US8636571B2 (en) | 2004-02-03 | 2014-01-28 | Cantor Index, Llc | System and method for managing select five horseracing bets |
| US9098883B2 (en) | 2004-02-03 | 2015-08-04 | Cantor Index, Llc | Managing bets that select events and participants |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| EP2947082A1 (en) * | 2009-11-10 | 2015-11-25 | Pfizer Inc | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| ES2546465T3 (es) | 2010-10-29 | 2015-09-23 | Pfizer Inc | Inhibidores de N1/N2-lactama acetil-CoA carboxilasa |
| AU2012245996B2 (en) | 2011-04-22 | 2016-09-01 | Pfizer Inc. | Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors |
| US8905832B2 (en) | 2012-01-30 | 2014-12-09 | Cfph, Llc | Event wagering with group and/or in run options |
| US11055967B2 (en) | 2014-03-26 | 2021-07-06 | Cfph, Llc | Event wagering with group and/or in run options |
| US20170178994A1 (en) * | 2015-12-21 | 2017-06-22 | Intel Corporation | Integrated circuit package support structures |
| KR102579876B1 (ko) | 2016-02-22 | 2023-09-18 | 삼성전자주식회사 | 반도체 패키지 |
| JP7266531B2 (ja) * | 2017-04-18 | 2023-04-28 | ジェンフィ | エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ |
| CN111406056B (zh) | 2017-11-21 | 2023-02-28 | 辉瑞公司 | 选择性acc抑制剂的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐 |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| US11254660B2 (en) | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
| WO2020234726A1 (en) | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| KR20220112811A (ko) | 2019-12-10 | 2022-08-11 | 화이자 인코포레이티드 | 2-((4-((S)-2-(5-클로로피리딘-2-일)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((S)-옥세탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카르복실산, 1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태 |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| HRP20241159T1 (hr) | 2020-02-07 | 2024-12-06 | Gasherbrum Bio, Inc. | Heterociklički agonisti za glp-1 |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2021155415A (ja) | 2020-03-27 | 2021-10-07 | ファイザー・インク | ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| CA3230347A1 (en) | 2021-08-31 | 2023-03-09 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| JP2025509281A (ja) | 2022-03-09 | 2025-04-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| AU2023364628A1 (en) | 2022-10-18 | 2025-04-03 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| TW202435857A (zh) | 2022-12-15 | 2024-09-16 | 美商迦舒布魯姆生物有限公司 | 具有glp-1促效劑活性之化合物之鹽及固體形式 |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025224648A1 (en) | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| CN1642599A (zh) | 2002-02-27 | 2005-07-20 | 辉瑞产品公司 | Acc抑制剂 |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004092179A1 (ja) | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| WO2005113069A2 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of circumin and analogues as inhibitors of acc2 |
| AP2006003768A0 (en) | 2004-05-25 | 2006-10-31 | Pfizer Prod Inc | TetraazabenzoÄeÜazulene derivatives and analogs tehereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2007011809A1 (en) | 2005-07-19 | 2007-01-25 | Merck & Co., Inc. | Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors |
| CA2617042A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| DE102006016566B4 (de) | 2005-09-22 | 2008-06-12 | Beru Ag | Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren |
| JP2009515971A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト |
| JP2009526868A (ja) | 2006-02-15 | 2009-07-23 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| BRPI0721053A2 (pt) | 2006-11-29 | 2014-07-29 | Pfizer Prod Inc | INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE |
| AU2008205642B2 (en) * | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| JPWO2008102749A1 (ja) * | 2007-02-20 | 2010-05-27 | 武田薬品工業株式会社 | 複素環化合物 |
| AU2008237660B2 (en) | 2007-04-12 | 2011-12-22 | Pfizer Inc. | 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| JP5435592B2 (ja) * | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| WO2009144555A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2010002010A1 (en) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co.,Ltd. | Novel spirochromanone carboxylic acids |
| AU2009271634A1 (en) | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| EP2947082A1 (en) * | 2009-11-10 | 2015-11-25 | Pfizer Inc | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| EP2499140A1 (en) * | 2009-11-10 | 2012-09-19 | Pfizer Inc. | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| HRP20161178T1 (hr) * | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| US20160034775A1 (en) | 2014-08-02 | 2016-02-04 | General Vault, LLC | Methods and apparatus for bounded image data analysis and notification mechanism |
-
2011
- 2011-09-20 HR HRP20161178TT patent/HRP20161178T1/hr unknown
- 2011-09-20 CA CA2811033A patent/CA2811033C/en active Active
- 2011-09-20 PT PT117681635T patent/PT2621493T/pt unknown
- 2011-09-20 US US13/876,211 patent/US8859577B2/en active Active
- 2011-09-20 ES ES11768163.5T patent/ES2602111T3/es active Active
- 2011-09-20 WO PCT/IB2011/054119 patent/WO2012042433A1/en not_active Ceased
- 2011-09-20 EP EP11768163.5A patent/EP2621493B1/en active Active
- 2011-09-20 SI SI201130951A patent/SI2621493T1/sl unknown
- 2011-09-20 PL PL11768163T patent/PL2621493T3/pl unknown
- 2011-09-20 DK DK11768163.5T patent/DK2621493T3/en active
- 2011-09-20 JP JP2013530829A patent/JP5824055B2/ja active Active
- 2011-09-20 HU HUE11768163A patent/HUE031616T2/hu unknown
- 2011-09-20 RS RS20160845A patent/RS55224B1/sr unknown
- 2011-09-20 LT LTEP11768163.5T patent/LT2621493T/lt unknown
-
2014
- 2014-09-19 US US14/491,016 patent/US9145416B2/en active Active
-
2015
- 2015-09-11 US US14/851,572 patent/US20150376185A1/en not_active Abandoned
-
2016
- 2016-08-15 US US15/236,635 patent/US9908883B2/en active Active
- 2016-09-13 CY CY20161100905T patent/CY1118016T1/el unknown
-
2018
- 2018-01-30 US US15/883,109 patent/US10294225B2/en active Active
-
2019
- 2019-04-01 US US16/371,896 patent/US10822335B2/en active Active
-
2020
- 2020-09-28 US US17/034,295 patent/US11673890B2/en active Active
-
2023
- 2023-05-03 US US18/311,715 patent/US20230322777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160347752A1 (en) | 2016-12-01 |
| DK2621493T3 (en) | 2016-10-24 |
| US20180162858A1 (en) | 2018-06-14 |
| US9145416B2 (en) | 2015-09-29 |
| US20150376185A1 (en) | 2015-12-31 |
| EP2621493A1 (en) | 2013-08-07 |
| CA2811033C (en) | 2015-10-20 |
| ES2602111T3 (es) | 2017-02-17 |
| JP5824055B2 (ja) | 2015-11-25 |
| SI2621493T1 (sl) | 2016-10-28 |
| HUE031616T2 (hu) | 2017-07-28 |
| EP2621493B1 (en) | 2016-08-17 |
| US20150011470A1 (en) | 2015-01-08 |
| US20130190334A1 (en) | 2013-07-25 |
| US20190218218A1 (en) | 2019-07-18 |
| PL2621493T3 (pl) | 2017-01-31 |
| US20210047325A1 (en) | 2021-02-18 |
| US11673890B2 (en) | 2023-06-13 |
| US10822335B2 (en) | 2020-11-03 |
| PT2621493T (pt) | 2016-11-14 |
| US20230322777A1 (en) | 2023-10-12 |
| US8859577B2 (en) | 2014-10-14 |
| RS55224B1 (sr) | 2017-02-28 |
| US10294225B2 (en) | 2019-05-21 |
| US9908883B2 (en) | 2018-03-06 |
| HRP20161178T1 (hr) | 2016-11-04 |
| CA2811033A1 (en) | 2012-04-05 |
| WO2012042433A1 (en) | 2012-04-05 |
| CY1118016T1 (el) | 2017-05-17 |
| JP2013540119A (ja) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2621493T1 (sl) | Zaviralci N1-pirazolospiroketon acetil-CoA-karboksilaze | |
| AP3283A (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
| ZA201303882B (en) | N1/n2-lactam acetyl-coa carboxylase inhibitors | |
| AP3499A (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
| TWI560172B (en) | Neprilysin inhibitors | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| PL2710007T3 (pl) | Inhibitory kinazy | |
| IL232958A (en) | Kinase inhibitors | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| IL229028A0 (en) | Kinase inhibitors | |
| GB201009731D0 (en) | Kinase inhibitors | |
| IL232959A0 (en) | Kinase inhibitors | |
| GB201002945D0 (en) | Access point | |
| GB201018597D0 (en) | Inhibitors | |
| GB201003502D0 (en) | Novel inhibitors | |
| GB201006605D0 (en) | Novel inhibitors | |
| GB201003936D0 (en) | Novel inhibitors | |
| GB201120474D0 (en) | Inhibitors | |
| GB201004912D0 (en) | Level |